Heparin Case Highlights Vulnerabilities of Global Supply Chain
This article was originally published in The Gold Sheet
Executive Summary
WHO'S NEXT? Baxter's heparin woes, related to a supply chain that stretches all the way to pig farms in China, raise questions about the ability of drug manufacturers to ensure the quality of drugs produced by globally sprawling enterprises. While the search for a root cause continues, some lessons already are clear: you can't always count on FDA or host nation regulators to police suppliers; you can't always be sure of your own ability to routinely detect deadly contaminants; and if something goes wrong, it could be front page news everywhere
You may also be interested in...
University Lab Crammed Too Late To Avoid US FDA Warning Letter
After a student analyst was caught fabricating Smithfield heparin data, Miami University chemistry department established a quality system and more than 20 quality procedures in time for an FDA inspection, but to no avail. The warning letter that followed was predicated on failures that had already occurred.
The Quality Lowdown: Import Alert Update
Crude heparin supplier Yibin Lihao headlines list of facilities in 12 countries added to the US FDA’s drug GMP import alert.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.